These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 34074904)

  • 1. Safety of Phosphodiesterase-5 Inhibitors in Valvular Heart Disease.
    Gopal A; Sharma T; Calkins JB
    J Cardiovasc Pharmacol; 2021 Sep; 78(3):372-376. PubMed ID: 34074904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphodiesterase type 5 inhibitors: state of the therapeutic class.
    Carson CC
    Urol Clin North Am; 2007 Nov; 34(4):507-15, vi. PubMed ID: 17983891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of phosphodiesterase-5 inhibitors for treating erectile dysfunction in kidney transplant recipients: a meta-analysis.
    Fanbin L; Mei Y; Yan Z; Yirong Y; Shaoling Z; Yong C; Peng X
    Exp Clin Transplant; 2014 Jun; 12(3):184-9. PubMed ID: 24907716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two Birds with One Stone: Regular Use of PDE5 Inhibitors for Treating Male Patients with Erectile Dysfunction and Cardiovascular Diseases.
    Cai Z; Zhang J; Li H
    Cardiovasc Drugs Ther; 2019 Feb; 33(1):119-128. PubMed ID: 30675707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of dapoxetine in men with premature ejaculation and concomitant erectile dysfunction treated with a phosphodiesterase type 5 inhibitor: randomized, placebo-controlled, phase III study.
    McMahon CG; Giuliano F; Dean J; Hellstrom WJ; Bull S; Tesfaye F; Sharma O; Rivas DA; Aquilina JW
    J Sex Med; 2013 Sep; 10(9):2312-25. PubMed ID: 23845016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Newer phosphodiesterase inhibitors: comparison with established agents.
    McNamara ER; Donatucci CF
    Urol Clin North Am; 2011 May; 38(2):155-63. PubMed ID: 21621082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacotherapeutic management of erectile dysfunction.
    Hawksworth DJ; Burnett AL
    Clin Pharmacol Ther; 2015 Dec; 98(6):602-10. PubMed ID: 26352006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis.
    Yuan J; Zhang R; Yang Z; Lee J; Liu Y; Tian J; Qin X; Ren Z; Ding H; Chen Q; Mao C; Tang J
    Eur Urol; 2013 May; 63(5):902-12. PubMed ID: 23395275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Minimal clinically important differences in the erectile function domain of the International Index of Erectile Function scale.
    Rosen RC; Allen KR; Ni X; Araujo AB
    Eur Urol; 2011 Nov; 60(5):1010-6. PubMed ID: 21855209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Optimization of the use of phosphodiesterase-5 inhibitors].
    Pushkar' DIu; Segal AS
    Urologiia; 2012; (4):79-80, 82. PubMed ID: 23116030
    [No Abstract]   [Full Text] [Related]  

  • 11. Erectile Dysfunction as a Cardiovascular Risk Factor: Time to Step Up?
    Imprialos K; Koutsampasopoulos K; Manolis A; Doumas M
    Curr Vasc Pharmacol; 2021; 19(3):301-312. PubMed ID: 32286949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SOP conservative (medical and mechanical) treatment of erectile dysfunction.
    Porst H; Burnett A; Brock G; Ghanem H; Giuliano F; Glina S; Hellstrom W; Martin-Morales A; Salonia A; Sharlip I;
    J Sex Med; 2013 Jan; 10(1):130-71. PubMed ID: 23343170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiac Effects of Phosphodiesterase-5 Inhibitors: Efficacy and Safety.
    Roy S; Kloner RA; Salloum FN; Jovin IS
    Cardiovasc Drugs Ther; 2023 Aug; 37(4):793-806. PubMed ID: 34652581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of nitric oxide in erectile dysfunction: implications for medical therapy.
    Burnett AL
    J Clin Hypertens (Greenwich); 2006 Dec; 8(12 Suppl 4):53-62. PubMed ID: 17170606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Understanding Erectile Dysfunction in Hypertensive Patients: The Need for Good Patient Management.
    Hernández-Cerda J; Bertomeu-González V; Zuazola P; Cordero A
    Vasc Health Risk Manag; 2020; 16():231-239. PubMed ID: 32606719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Continuous use of PDE5 inhibitors in the treatment of erectile dysfunction: New insights and opportunities].
    Puigvert AM; Prieto R; García F
    Rev Int Androl; 2018; 16(1):28-33. PubMed ID: 30063020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationale for phosphodiesterase 5 inhibitor use post-radical prostatectomy: experimental and clinical review.
    Rambhatla A; Kovanecz I; Ferrini M; Gonzalez-Cadavid NF; Rajfer J
    Int J Impot Res; 2008; 20(1):30-4. PubMed ID: 17673932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BPH/LUTS and ED: common pharmacological pathways for a common treatment.
    Fusco F; D'Anzeo G; Sessa A; Pace G; Rossi A; Capece M; d'Emmanuele di Villa Bianca R
    J Sex Med; 2013 Oct; 10(10):2382-93. PubMed ID: 23875757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Importance of patient's choice in the treatment of erectile dysfunction].
    Corman A; Chevret-Méasson M; Gehchan N
    Presse Med; 2012 Jun; 41(6 Pt 1):593-7. PubMed ID: 22377459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selectivity of avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction: implications for clinical safety and improved tolerability.
    Wang R; Burnett AL; Heller WH; Omori K; Kotera J; Kikkawa K; Yee S; Day WW; DiDonato K; Peterson CA
    J Sex Med; 2012 Aug; 9(8):2122-9. PubMed ID: 22759639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.